Clinical Trials Logo

Hemangioma, Capillary clinical trials

View clinical trials related to Hemangioma, Capillary.

Filter by:

NCT ID: NCT02731287 Completed - Hemangioma Clinical Trials

Topical Timolol for Infantile Hemangioma in Early Proliferative Phase

Start date: March 2014
Phase: Phase 2
Study type: Interventional

Infantile hemangioma (IH) is the most common benign vascular tumor in pediatric population. Oral propranolol is the treatment of choice for complicated hemangiomas. Topical timolol, a non-selective beta-blocker, is an emerging treatment which has been reported to be effective and safe for the treatment of IH, especially for superficial hemangiomas. Investigators hypothesize that treatment with topical timolol in the first two months of life, before the proliferative phase or in early proliferative phase, may prevent from further growing and the need to treat with oral propranolol.

NCT ID: NCT02505971 Completed - Clinical trials for Infantile Hemangioma

Nadolol Versus Propranolol in Children With Infantile Hemangiomas

Start date: September 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of oral propranolol versus nadolol in patients with Infantile Hemangiomas (IH) in a randomized, controlled, double-blinded study.

NCT ID: NCT02342275 Completed - Hemangioma Clinical Trials

Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma

Start date: October 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of orally administered propranolol versus atenolol in the treatment of potentially disfiguring or functionally threatening IHs.

NCT ID: NCT02317679 Completed - Port-wine Stains Clinical Trials

Treatment of Resistant Port-wine Stains With Bosentan and Pulsed Dye Laser: a Pilot Study

Start date: April 2014
Phase: Phase 2
Study type: Interventional

Pulsed dye laser (PDL) is the gold standard treatment for port-wine stains (PWS). However, the outcomes are highly variable due to the new angiogenesis occurring after laser irradiation. Studies suggest that endothelin is involved in the neoangiogenesis that occurred after treatment of port-wine stains by PDL. The main objective of this pilot clinical trial is to evaluate the effectiveness and safety of an inhibitor of endothelin orally taken, the Bosentan, following PDL treatment. Four patients with facial port-wine stain resistant to the PDL treatment will be included. The treatment by Bosentan (2 mg/kg twice daily, maximum 62,5 mg twice daily) will be given one day before the PDL irradiation and continued for 14 days. Only one test area of PWS will be treated with PDL. The primary outcome measure will be an important or complete improvement (Investigator Global Assessment 3 or 4) between treated area and non treated one, 14 days after the end of the treatment which corresponds to one month after the laser PDL session. The evaluation will been performed on standardized pictures by 2 independent physicians blinded to the region treated or not.

NCT ID: NCT02145884 Completed - Hemangioma Clinical Trials

Topical Timolol Gel for the Treatment of Infantile Hemangiomas

Start date: May 2014
Phase: Phase 2
Study type: Interventional

We plan to conduct a study, to see how safe and effective timolol maleate 0.5% gel-forming solution is for infantile hemangiomas (IH) and the response of hemangiomas to timolol maleate 0.5% . Our hypothesis is that timolol will inhibit and possibly reverse growth of appropriate infantile hemangiomas.

NCT ID: NCT02061735 Completed - Clinical trials for Infantile Hemangiomas

Ontogeny of Infantile Hemangiomas With Skin Imaging Modalities

Start date: October 2011
Phase: N/A
Study type: Observational

A combined set of quantitative skin imaging methods will quantitatively describe the natural ontogeny and the response to standard treatments over time in patients with infantile hemangiomas.

NCT ID: NCT02051101 Completed - Port-Wine Stain Clinical Trials

Pathogenic Mechanisms of Port Wine Stain and Repository of Port Wine Stain Biopsy Samples

Start date: April 23, 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the pathogenic mechanisms of Port Wine Stain, collect biopsy samples and blood samples to characterize exosomes and metabolites from Port Wine Stain.

NCT ID: NCT01924273 Completed - Port-Wine Stain Clinical Trials

Novel Treatment for Port Wine Stain Birthmarks

Start date: June 2013
Phase: Phase 1
Study type: Interventional

Port wine stains Birthmark are congenital, progressive vascular malformations of the skin that occur in approximately 0.7% of newborns. Approximately 1.5 million individuals in the United States and 32 million people worldwide have Port wine stains birthmarks. Two-thirds of these malformations occur on the face. Personality development of virtually all patients is adversely affected as a result of the negative reaction of others to a "marked" person. Detailed studies have documented lower self-esteem and difficulties with interpersonal interactions in Port wine stains patients. Port wine stains are initially flat and red, but with time, they tend to darken to purple and become thickened as vascular nodules develop. This thickening occurs in approximately two-thirds of lesions and further disfigures the facial features of many patients.

NCT ID: NCT01775722 Completed - Port-Wine Stain Clinical Trials

Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment

Start date: December 2012
Phase: N/A
Study type: Interventional

Port wine stain Birthmark is a congenital, progressive vascular malformation of human skin. However, even though the pulsed dye laser is considered as the treatment of choice for Port wine stain Birthmark the degree of fading can remain variable and unpredictable after laser treatment.

NCT ID: NCT01774552 Completed - Port-wine Stain Clinical Trials

Evaluate the Port-wine Stain Birthmark Treatment Before and After Pulsed Dye Laser Treatment

Start date: December 2012
Phase:
Study type: Observational

Port-wine stain is a congenital, progressive vascular malformation of human skin involving post-capillary venules that occurs in an estimated 0.3% of children and can alter personality development and psychological in children.